Solid Tumor Testing Market Size, Share, Growth, and Industry Analysis, By Type (Conventional testing, Non-conventional testing), By Application (Hospitals, Diagnostic laboratories, Academic and research institutes), Regional Insights and Forecast to 2035
Solid Tumor Testing Market Overview
The global Solid Tumor Testing Market is projected to expand steadily from USD 29570.31 Million in 2026 to USD 52987.68 Million by 2035, representing a CAGR of 6.69% during 2026-2035.
The Solid Tumor Testing Market is experiencing significant transformation as healthcare providers increasingly adopt molecular diagnostics, precision oncology, and biomarker-guided treatment strategies. Solid tumor testing encompasses conventional pathology examinations, immunohistochemistry, molecular profiling, and advanced blood-based diagnostic technologies used to characterize malignant tumors. Conventional testing accounted for approximately 57% of the global market in a assessment, reflecting the established importance of tissue evaluation and routine diagnostic procedures. The growing integration of next-generation sequencing, circulating tumor DNA analysis, and comprehensive genomic profiling is expanding testing capabilities. Healthcare organizations increasingly require accurate identification of actionable mutations, treatment resistance mechanisms, and disease progression indicators. Pharmaceutical innovation and the availability of targeted cancer therapies are encouraging broader adoption of companion diagnostics.
The United States Solid Tumor Testing Market benefits from extensive cancer diagnostic infrastructure, established molecular laboratories, expanding clinical oncology programs, and favorable access to advanced genomic technologies. North America represented approximately 42% of global solid tumor testing demand in a industry assessment, with the United States accounting for a substantial portion of regional testing activity. Healthcare institutions increasingly incorporate biomarker profiling into treatment selection for lung, breast, colorectal, and other solid malignancies. Blood-based genomic testing is becoming more important when tumor tissue is insufficient or difficult to obtain.
Key Findings
- Key Market Driver: Increasing adoption of precision oncology and biomarker-guided treatment is accelerating solid tumor testing demand, with tissue-based diagnostic procedures accounting for approximately 61.23% of market activity.
- Major Market Restraint: High molecular testing costs, reimbursement limitations, and complex laboratory requirements restrict wider adoption, while conventional testing maintains approximately 57% market share due to established clinical accessibility.
- Emerging Trends: Liquid biopsy and circulating tumor DNA analysis are transforming cancer diagnostics, with blood-based testing projected to expand at approximately 15.55% annually through 2031, supporting minimally invasive molecular profiling.
- Regional Leadership: North America leads the Solid Tumor Testing Market with approximately 42% global market share, supported by advanced diagnostic infrastructure, established molecular laboratories, and widespread adoption of precision oncology.
- Competitive Landscape: F. Hoffmann-La Roche Ltd. remains a prominent molecular oncology diagnostics provider, operating within a leading supplier group that collectively accounts for approximately 48% of the broader oncology molecular diagnostics market.
- Market Segmentation: Conventional testing dominates the Solid Tumor Testing Market with approximately 57% market share, supported by established tissue pathology procedures, widespread hospital adoption, and routine diagnostic applications.
- Recent Development: Guardant Health received expanded regulatory approval for its blood-based genomic profiling platform in May, addressing a liquid biopsy segment projected to grow approximately 15.55% annually through 2031.
Solid Tumor Testing Market Latest Trends
The Solid Tumor Testing Market is increasingly shifting toward comprehensive molecular profiling and minimally invasive diagnostic procedures. Next-generation sequencing enables simultaneous examination of multiple cancer-related genetic alterations, improving opportunities for targeted therapy selection and clinical trial matching. Blood-based testing is becoming particularly important for patients whose tumor tissue is unavailable, insufficient, or difficult to collect repeatedly. Liquid biopsy is projected to grow at approximately 15.55% annually through , reflecting increasing demand for accessible genomic monitoring.
Another important market trend involves integration of artificial intelligence, digital pathology, and longitudinal molecular monitoring into cancer diagnostic workflows. Advanced laboratory platforms increasingly combine conventional tissue assessment with genomic analysis to generate comprehensive tumor profiles. Diagnostic and reference laboratories are projected to expand at approximately 10.11% annually in one market assessment, supported by increasing demand for specialized testing capabilities.
Solid Tumor Testing Market Dynamics
Driver
"Increasing adoption of precision oncology accelerates diagnostic demand."
The expanding use of targeted cancer therapies is a primary driver of the Solid Tumor Testing Market. Treatment selection increasingly depends on identifying specific genetic alterations, protein expression patterns, and molecular characteristics associated with therapeutic response. Tissue-based diagnostic procedures represented approximately 61.23% of market activity in a assessment, demonstrating their continued importance in establishing tumor characteristics and supporting subsequent molecular analysis. Healthcare providers increasingly require reliable testing for actionable biomarkers before initiating certain oncology treatments.
Growing demand for comprehensive genomic profiling provides an additional structural growth driver. Clinical oncology increasingly incorporates molecular results into treatment selection, particularly when established therapies depend on specific genomic findings. Lung cancer testing is projected to expand at approximately 10.85% annually through in one industry assessment, supported by growing use of biomarker-directed treatments. Testing laboratories are consequently strengthening sequencing capabilities, specimen management, and molecular interpretation services. Pharmaceutical companies also collaborate with diagnostic developers to support companion diagnostic availability alongside new therapeutic approvals.
Restraint
"High testing costs and reimbursement limitations restrict wider adoption."
Advanced solid tumor testing involves specialized instruments, qualified laboratory professionals, complex sample preparation, and sophisticated molecular interpretation. These requirements create substantial financial and operational barriers, particularly for healthcare organizations with limited diagnostic infrastructure. Conventional testing maintained approximately 57% market share in a assessment, partly reflecting the established availability of routine pathology and comparatively accessible diagnostic procedures. Although molecular assays offer valuable biomarker information, their implementation requires investment in sequencing equipment, quality management, laboratory information systems, and personnel training.
Sample limitations and inconsistent access to specialist testing facilities create further obstacles. Solid tumor specimens can contain insufficient tumor material, degraded nucleic acids, or biological characteristics that complicate molecular analysis. Tissue samples represented approximately 61% of the assessed market, emphasizing the continuing importance of specimen collection and preservation. Repeated invasive biopsies may be unsuitable for some patients, while circulating tumor DNA assays can produce negative findings when tumor DNA shedding is limited.
Opportunity
"Liquid biopsy expansion creates new precision oncology opportunities."
Increasing clinical interest in minimally invasive cancer testing creates important opportunities for manufacturers developing circulating tumor DNA assays and comprehensive molecular diagnostic platforms. Liquid biopsy is projected to expand at approximately 15.55% annually through 2031, supported by demand for blood-based mutation detection and longitudinal disease assessment. These technologies can provide molecular information when tumor tissue cannot be obtained or when repeated tissue sampling is clinically impractical. Diagnostic developers are improving analytical sensitivity, genomic coverage, and bioinformatics interpretation.
Emerging healthcare markets provide additional opportunities through expansion of oncology services, molecular laboratory infrastructure, and access to personalized medicine. Diagnostic and reference laboratories are projected to experience approximately 10.11% annual growth in one market outlook, reflecting increasing requirements for specialized genomic analysis. Regional laboratories are adopting automated molecular workflows and developing partnerships with healthcare providers to improve test availability. Academic institutions also contribute through translational research, biomarker validation, and prospective clinical studies.
Challenge
"Complex molecular interpretation creates clinical implementation challenges."
The increasing complexity of molecular oncology testing creates challenges involving analytical validation, clinical interpretation, and communication of actionable findings. Modern comprehensive genomic profiling systems can examine hundreds of genes, generating extensive molecular information requiring specialized assessment. In one market forecast, liquid biopsy adoption is expected to increase at approximately 15.55% annually, reinforcing the need for dependable data interpretation and standardized reporting.
Maintaining consistent quality across conventional and non-conventional testing technologies presents another challenge. Tissue-based analysis represented approximately 61.23% of solid tumor testing activity in a assessment, making specimen processing and pathological evaluation central to diagnostic accuracy. Differences in tissue preservation, tumor purity, assay sensitivity, and laboratory procedures can influence results. Liquid biopsy testing introduces additional considerations involving circulating DNA concentration, biological variation, and interpretation of negative findings.
Solid Tumor Testing Market Segmentation
By Types
Conventional testing: Conventional testing represents the largest product-type segment, accounting for approximately 57% of the global Solid Tumor Testing Market in a assessment. This category includes established diagnostic approaches used for tumor identification, tissue characterization, and routine pathological examination. Histopathology, immunohistochemistry, and related diagnostic procedures remain fundamental components of oncology workflows because they provide essential information about tumor morphology, differentiation, and biomarker expression. Hospitals and diagnostic laboratories rely on these methods to confirm malignancy and guide additional testing requirements.
Non-conventional testing: Non-conventional testing accounts for approximately 43% of the assessed market when measured as the remaining share of the conventional and non-conventional classification. This category encompasses advanced molecular and emerging diagnostic approaches, including comprehensive genomic profiling, circulating tumor DNA analysis, and sophisticated biomarker detection. Demand is supported by expanding precision oncology applications and increasing availability of targeted cancer therapies. Molecular tests can identify clinically relevant genomic alterations that conventional examination alone may not reveal.
By Applications
Hospitals: Hospitals represent an important application segment because solid tumor testing is closely integrated with cancer diagnosis, surgery, treatment planning, and multidisciplinary oncology services. Hospital laboratories accounted for approximately 60% of combined molecular and conventional assay volume in a reported 2024 assessment. Hospitals perform tissue examinations, immunohistochemistry, and selected molecular assays while referring more complex analyses to specialist laboratories when necessary. Access to patient records, pathology departments, and oncology specialists supports coordinated diagnostic decision-making. Increasing adoption of biomarker-guided therapies encourages hospitals to expand molecular testing access and improve specimen processing, laboratory communication, and clinical reporting.
Diagnostic laboratories: Diagnostic laboratories provide specialized molecular profiling, tissue-based biomarker analysis, and advanced blood-based cancer testing services. One industry assessment assigned this application approximately 30% market share, reflecting its important contribution to outsourced oncology diagnostics. Reference laboratories frequently maintain high-throughput sequencing systems, specialized molecular personnel, and validated testing procedures supporting complex clinical requirements. Centralized testing enables healthcare providers to access comprehensive genomic profiling without independently operating advanced diagnostic platforms. Laboratories increasingly offer integrated tumor mutation analysis, companion diagnostics, and longitudinal monitoring services, supported by growing demand for personalized oncology care.
Academic and research institutes: Academic and research institutes contribute to the Solid Tumor Testing Market through biomarker discovery, translational oncology, diagnostic validation, and clinical research. Their application share has not been independently established in a comparable three-category market dataset, although a broader industry assessment indicates approximately 15.55% projected annual growth for liquid biopsy testing, an important area of academic investigation. Research institutions evaluate emerging molecular technologies, investigate tumor heterogeneity, and examine relationships between genomic alterations and treatment response. Their activities support the development of clinically useful diagnostic assays and contribute evidence required for future adoption.
Solid Tumor Testing Market Regional Outlook
North America
North America leads the Solid Tumor Testing Market, accounting for approximately 42% of global demand in a assessment. Advanced healthcare infrastructure, established molecular laboratories, and widespread adoption of precision oncology support regional leadership. The United States maintains extensive capabilities in genomic profiling, companion diagnostics, and specialized cancer testing. Hospitals increasingly incorporate molecular information into treatment selection for solid malignancies. Regulatory approvals and reimbursement arrangements also support access to clinically validated technologies.
North America's approximately 42% market share reflects its established cancer diagnostic infrastructure and continued investment in molecular medicine. Reference laboratories increasingly provide comprehensive genomic profiling and blood-based tumor analysis to healthcare institutions. Academic medical centers contribute through biomarker validation, clinical studies, and translational research. Demand is supported by personalized treatment strategies and increasing recognition of molecular testing throughout cancer management. Nevertheless, reimbursement variation and testing accessibility remain important considerations for hospitals and patients.
Europe
Europe represents an established solid tumor testing region, supported by public healthcare systems, cancer research networks, and advanced pathology laboratories. Liquid biopsy technologies, projected to grow globally at approximately 15.55% annually, are attracting interest among European oncology specialists. Healthcare providers increasingly combine tissue examination with genomic profiling to support targeted treatment selection. Regulatory requirements encourage diagnostic manufacturers to strengthen clinical validation and product documentation.
European diagnostic laboratories are strengthening capabilities in companion diagnostics, digital pathology, and advanced sequencing. Tissue-based testing, representing approximately 61.23% of the assessed global market, remains central to cancer diagnosis and pathological characterization. Healthcare organizations increasingly develop coordinated testing pathways between hospitals and specialist laboratories. Clinical research partnerships also support investigation of blood-based tumor monitoring.
Asia-Pacific
Asia-Pacific represents an important growth region for solid tumor testing, supported by expanding cancer care infrastructure, genomic research, and increasing availability of molecular diagnostics. Lung cancer testing is projected to grow globally at approximately 10.85% annually, highlighting opportunities for regional laboratories serving substantial oncology populations. China, Japan, South Korea, and India are strengthening molecular diagnostic capabilities through laboratory development and clinical research. Increasing adoption of targeted therapies is encouraging broader biomarker testing.
Asia-Pacific diagnostic providers are increasingly adopting next-generation sequencing, tissue biomarker analysis, and blood-based genomic testing. Non-conventional testing represents approximately 43% of the assessed global market by type, illustrating the importance of advanced molecular approaches. Regional manufacturers and laboratories are developing scalable diagnostic systems suited to different healthcare settings. Academic institutions contribute to cancer genomics research and molecular assay development.
Middle East and Africa
The Middle East and Africa Solid Tumor Testing Market is developing through healthcare infrastructure investment, specialized oncology services, and expanding diagnostic laboratory capacity. Conventional testing accounts for approximately 57% of the assessed global market, reflecting the importance of established pathology methods in healthcare systems with different technological capabilities. Major medical centers increasingly introduce molecular diagnostic services to support targeted cancer treatment. Demand for reliable tissue examination, biomarker identification, and laboratory quality assurance continues to influence equipment procurement and clinical testing strategies.
Regional opportunities are emerging through hospital modernization, specialist laboratory partnerships, and improved access to cancer diagnostic services. Diagnostic and reference laboratories are projected to grow globally at approximately 10.11% annually, demonstrating the potential importance of centralized molecular testing capabilities. Healthcare organizations increasingly explore specimen referral networks to access advanced diagnostics. Challenges include infrastructure limitations, testing affordability, specialist workforce availability, and reimbursement differences. Continued development of oncology care facilities may gradually improve access to molecular testing.
Rest of the World
Rest of the World markets, particularly Latin American healthcare systems, offer opportunities through expanding oncology services and improving molecular diagnostic infrastructure. Tissue-based analysis represents approximately 61.23% of the assessed global market, demonstrating the continuing relevance of established pathology capabilities. Regional hospitals increasingly require reliable tumor classification, biomarker identification, and appropriate referral pathways. Diagnostic manufacturers are developing scalable solutions that support routine testing while enabling gradual introduction of advanced genomic technologies.
Growing clinical interest in personalized oncology is encouraging investment in diagnostic laboratories and molecular testing partnerships. Liquid biopsy is projected to expand globally at approximately 15.55% annually, presenting opportunities for specialized laboratories as clinical adoption broadens. Healthcare organizations are evaluating technologies that improve testing accessibility and reduce dependence on repeated invasive procedures. Market expansion remains influenced by laboratory infrastructure, availability of trained specialists, regulatory requirements, and affordability.
List of Top Solid Tumor Testing Market Companies
- Abbott Laboratories
- Illumina, Inc.
- F. Hoffmann-La Roche Ltd.
- Bio-Rad Laboratories, Inc.
- Beijing Genomics Institute (BGI)
- QIAGEN N.V.
- ASURAGEN, INC.
- NeoGenomics Laboratories, Inc.
- Invivoscribe, Inc.
- Inviate Corporation
- Opko Health
- Laboratory Corporation of American Holdings
- OmniSeq
- Guardant Health
Top Two Companies with Highest Market Share
- F. Hoffmann-La Roche Ltd.: Roche is an established participant in tissue pathology, molecular diagnostics, and companion diagnostic development. A broader oncology molecular diagnostics assessment estimated that five major suppliers collectively represented approximately 48% of that market, although Roche's individual share of solid tumor testing was not disclosed.
- Illumina, Inc.: Illumina maintains a leading position in next-generation sequencing technology, with an estimated 77% share of the broader DNA sequencing market in 2025. Its TruSight Oncology Comprehensive platform supports comprehensive genomic profiling and detection of clinically relevant mutations in solid tumors.
Investment Analysis and Opportunities
Investment in the Solid Tumor Testing Market is increasingly focused on comprehensive genomic profiling, laboratory automation, advanced sequencing, and blood-based molecular diagnostics. Liquid biopsy is projected to grow approximately 15.55% annually through attracting interest in sensitive circulating tumor DNA detection and longitudinal cancer monitoring. Manufacturers are improving automated sample preparation, integrated reporting, and analytical interpretation. Investment opportunities also exist in clinically validated companion diagnostics supporting biomarker-directed therapies and pharmaceutical development programs.
Diagnostic laboratories are expanding molecular capabilities to address increasing demand for personalized oncology services. Reference laboratory testing is projected to grow approximately 10.11% annually in one industry assessment, supporting investment in high-throughput sequencing and specialized analytical infrastructure. Healthcare organizations increasingly seek integrated diagnostic pathways combining tissue characterization with molecular profiling. Companies developing efficient workflows, reliable assay performance, and clinical decision-support capabilities may strengthen their competitive positions.
New Product Development
New product development in the Solid Tumor Testing Market increasingly emphasizes comprehensive tumor profiling, advanced mutation detection, and clinically validated companion diagnostic applications. Non-conventional testing accounts for approximately 43% of the assessed market, highlighting the growing importance of advanced molecular technologies. Illumina's TruSight Oncology Comprehensive platform supports detection of clinically relevant genomic alterations in solid tumor tissue, improving biomarker identification and personalized treatment selection. Manufacturers are developing assays with enhanced analytical sensitivity, automated specimen preparation, and integrated bioinformatics interpretation to support more efficient oncology diagnostic workflows.
Blood-based cancer testing is becoming an important product development priority, with liquid biopsy projected to grow approximately 15.55% annually through 2031. In May 2026, Guardant Health received expanded regulatory approval for its Guardant360 Liquid CDx platform, strengthening comprehensive genomic profiling through blood-based mutation detection. The technology supports selected companion diagnostic applications and enables molecular assessment when tumor tissue is insufficient or difficult to obtain. Manufacturers are also advancing circulating tumor DNA analysis, epigenomic testing, and molecular residual disease detection to improve cancer monitoring and precision oncology applications.
Five Recent Developments
- February 2026 – NeoGenomics Expands Molecular Residual Disease Testing: NeoGenomics launched RaDaR ST, a circulating tumor DNA assay designed to support molecular residual disease detection across multiple solid tumor types. The development broadens its oncology testing portfolio.
- May 2026 – Guardant Health Receives Expanded Liquid Biopsy Approval: Guardant Health received FDA approval for its expanded Guardant360 Liquid CDx platform, strengthening blood-based comprehensive genomic profiling and selected companion diagnostic applications.
- June 2026 – Roche Expands Precision Oncology Diagnostic Capabilities: Roche received regulatory approval for its VENTANA PTEN companion diagnostic assay in prostate cancer, supporting biomarker identification for treatment selection.
- August 2026 – Illumina Advances Comprehensive Solid Tumor Profiling: Illumina received an expanded regulatory indication for TruSight Oncology Comprehensive covering RET alterations in thyroid cancer, strengthening the platform's companion diagnostic applications.
- September 2026 – Guardant Health Advances Biomarker Guided Breast Treatment: Guardant Health received approval for Guardant360 CDx as a companion diagnostic identifying ESR1 mutations associated with eligibility for camizestrant-based treatment in advanced breast cancer.
Future Outlook
The Solid Tumor Testing Market is expected to evolve through expanding precision oncology applications, advanced genomic profiling, and greater integration of molecular diagnostics into clinical practice. Advanced molecular platforms will increasingly complement established pathological examination through improved biomarker identification and genomic analysis. Healthcare providers are expected to require reliable diagnostic information for therapy selection, treatment resistance assessment, and ongoing disease monitoring. Improvements in laboratory automation, molecular testing accuracy, and clinical interpretation will support continued market development.
Long-term growth opportunities will increasingly involve liquid biopsy, molecular residual disease assessment, integrated genomic analysis, and standardized companion diagnostics. Blood-based testing is projected to grow approximately reflecting increasing clinical interest in minimally invasive molecular evaluation. Manufacturers are expected to prioritize analytical validation, accessible testing workflows, improved diagnostic sensitivity, and expanded biomarker coverage. Hospitals, diagnostic laboratories, and academic institutions will remain important participants in developing and implementing advanced oncology diagnostic technologies, supporting wider adoption of precision medicine and personalized cancer treatment strategies.
Solid Tumor Testing Market Report Coverage
| REPORT COVERAGE | DETAILS | |
|---|---|---|
|
Market Size Value In |
USD 29570.31 Million in 2026 |
|
|
Market Size Value By |
USD 52987.68 Million by 2035 |
|
|
Growth Rate |
CAGR of 6.69% from 2026-2035 |
|
|
Forecast Period |
2026 - 2035 |
|
|
Base Year |
2025 |
|
|
Historical Data Available |
Yes |
|
|
Regional Scope |
Global |
|
|
Segments Covered |
By Type :
By Application :
|
|
|
To Understand the Detailed Market Report Scope & Segmentation |
||
Frequently Asked Questions
The global Solid Tumor Testing Market is expected to reach USD 52987.68 Million by 2035.
The Solid Tumor Testing Market is expected to exhibit a CAGR of 6.69% by 2035.
Abbott Laboratories, Illumina, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Beijing Genomics Institute (BGI), QIAGEN N.V., ASURAGEN, INC., NeoGenomics Laboratories, Inc., Invivoscribe, Inc., Inviate Corporation, Opko Health, Laboratory Corporation of American Holdings, OmniSeq, Guardant Health
In 2026, the Solid Tumor Testing Market value will reach at USD 29570.31 Million.